Clover Health Investments Corp is trading 4.3% up today at $5.02, extending a sharp multi-day advance. - This rally has been primarily driven by a recent court-ordered upgrade of its 2026 Medicare Star Rating from 3.5 to 4.5 stars, which is anticipated to positively influence 2027 payments and reimbursements. - Further contributing to investor sentiment, UBS recently increased its price target for CLOV on June 11, reflecting growing confidence in the company's trajectory.